OSU6162 as add-on in SSRI/SNRI-resistant Depression
Status:
Recruiting
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
This is a randomised, placebo-controlled, parallel-group trial comparing OSU6162 at flexible
dosage with placebo as add-on to treatment with an SSRI/SNRI in patients with depression that
have not responded to treatment with an SSRI/SNRI per se for at least 6 weeks. The study will
last for 6 weeks, after which those not having responded will leave the trial and those
having responded will be offered to continue treatment without unblinding for another 4
weeks.
While assessment of the efficacy and safety of OSU6162 is the main objective of this study,
possible differences between the two treatment groups with respect to a number of biomarkers
in serum will also be explored.